回生口服液联合吉非替尼治疗晚期EGFR突变阳性非小细胞肺癌的疗效及凝血功能的影响  

Clinical efficacy and the effect on coagulation function of Huisheng Oral Liquid combined with gefitinib on advanced EGFR mutation-positive non-small cell lung cancer

作　　者：谢莹慧 靳照 张黎昕 吴乾[2] XIE Ying-hui;JIN Zhao;ZHANG Li-xin(Shanxi University of Chinese Medicine,Taiyuan 030024,China;不详)

机构地区：[1]山西中医药大学,太原030024 [2]山西省肿瘤医院,太原030013

出　　处：《中国处方药》2023年第3期142-145,共4页Journal of China Prescription Drug

摘　　要：目的探讨回生口服液与吉非替尼联合治疗对晚期表皮生长因子受体(EGFR)突变阳性非小细胞肺癌(NSCLC)患者的近期临床疗效及凝血功能的影响。方法将60例患者按随机表法随机分为对照组与观察组,对照组给予吉非替尼治疗,观察组在对照组基础上给予回生口服液治疗。比较两组患者的近期临床疗效、凝血功能以及生存质量改善情况。结果治疗后,观察组近期疗效的客观缓解率(ORR)高于对照组(P<0.05)。两组患者的凝血酶原时间(PT)均有所延长,对照组PT延长较观察组更明显(P<0.05);两组活化部分凝血酶原时间(APTT)均有所缩短,对照组APTT缩短较观察组更明显(P<0.05);两组纤溶蛋白原(FIB)、D-二聚体(D-D)均有所升高,对照组FIB、D-D升高较观察组更明显(P<0.05)。观察组卡氏评分改善率高于对照组(P<0.05)。结论回生口服液联合吉非替尼,可提高EGFR突变阳性NSCLC患者的近期临床疗效,调节凝血功能异常,改善生存质量。Objective To investigate the effect of Huisheng Oral Liquid combined with gefitinib on the short-term clinical efficacy and coagulation function of patients with advanced epidermal growth factor receptor(EGFR)mutation-positive non-small cell lung cancer(NSCLC).Methods 60 patients were randomly divided into the control group and the observation group according to random table method.The control group was given gefitinib treatment,and the observation group was given Huisheng Oral Liquid treatment on the basis of the control group.The shortterm clinical efficacy,coagulation function and improvement of quality of life were compared between the two groups.Results After treatment,the objective response rate(ORR)in the observation group was higher than that in the control group(P<0.05).Prothrombin time(PT)was prolonged in both groups,and the prothrombin time in control group was more obvious than that in observation group(P<0.05).Activated partial thrombin time(APTT)was decreased in both groups,and the reduction of APTT in control group was more obvious than that in observation group(P<0.05).Fibrinogen(FIB)and D-dimer(D-D)were increased in both groups,and the increase of FIB and D-D in the control group was more obvious than that in observation group(P<0.05).The improvement rate of KPS score in the observation group was significantly higher than that in the control group(P<0.05).Conclusion Huisheng Oral Liquid combined with gefitinib in the treatment of patients with advanced EGFR mutation-positive NSCLC can improve the short-term efficacy,regulate coagulation dysfunction and improve the quality of life.

关 键 词：回生口服液 吉非替尼 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]